World / Science & Health Nov 19, 2020
Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'
Final trial results showed the vaccine had a 95% success rate and no serious side effects, the drugmakers said.
Pfizer-BioNTech coronavirus vaccine deliveries could start 'before Christmas'
Final trial results showed the vaccine had a 95% success rate and no serious side effects, the drugmakers said.
How Pfizer and BioNTech sprinted ahead in extraordinary race for a COVID-19 vaccine
Researchers were asked to tackle something that had never been done before: design a vaccine to stop a pandemic in its tracks in less than a year.
Here’s to the immigrant heroes behind the BioNTech vaccine
Their journey as Turkish Germans cannot have been easy. Discrimination, overt or subtle, is rife in German society.
What happens to the other COVID-19 vaccines now?
If the vaccine created by Pfizer and partner BioNTech fails to live up to its promise, will any slower but better competitors have a chance?
Pfizer COVID-19 vaccine trial reports no major safety issues
Safety has been a paramount concern since AstraZeneca paused tests of the vaccine it's co-developing with the University of Oxford following an adverse event in a U.K.
Japan and AstraZeneca set for deal on 100 million doses of virus vaccine
The drugmaker is expected to begin clinical trials in Japan later this month to confirm the efficacy and safety of its vaccine, currently being tested overseas.
Japan and Pfizer reach COVID-19 vaccine deal to treat 60 million people
The agreement marks Japan's first advance deal for a vaccine to fight the coronavirus.
Pfizer and BioNTech coronavirus vaccine candidates on FDA fast track
The U.S.-listed shares of the German firm climbed about 15 percent, while Pfizer's stock rose about 5 percent.